Member Info for BuenaVista

Ha ha. That carmooner post didn't last long!

Oh look! It's the Dunning–Kruger Kid.

So many egotistical idiots

Argung with a troll is a fool's game.

Please just ignore the trolls. They are ignorant and add nothing except clutter.

Best to switch it off.

Stupid questions from a stupid troll.

O how I've missed the Trades threads. The old ones are the best.

@LL, strictly speaking doxorubicin is administered as often and in such quantity as the body can stand. That might be 60-75mg/m² every 3 weeks or 20mg/m² every week.

@everyone, thornogson, like the windbag and the carmooner, is just a waste of time who is worthy of only one response, namely "F*** off you time waster."

Hi what's stuck thanks.

I can't buy on HL.

But that's because I haven't got any available cash.

Avacta really need to get their excellent preclinical and clinical findings into the peer-reviewed literature. So far there has been... nothing, except for conference posters (not even public presentations open to comment and thus not in any way peer-reviewed) and patents (from Bachovchin and only concerned with prior art, not efficacy).

Https://www.londonstockexchange.com/news-article/OBD/obd-pursuing-episwitch-as-companion-diagnostics/16585152

This was a Reach rather than a RNS which is why no red dot here.

Save this and run it at 7:01 every business day morning and you'll never miss any OBD or wider diagnostics and pharma industry announcements: https://www.londonstockexchange.com/news?tab=news-explorer§ors=201020,201030

How do i refrain thanks.

Still not found the Reply link then toastie

Where can i wash my clothes thanks.

Last trial update was 4 weeks ago, 26 June (AGM day). If CC really said the 3rd patient was going to be dosed later that day then the 2 doses and final two week observation period finishes today. All being well, now waiting for SDMC to meet and pronounce judgement. And possibly for some other news that the C3 completion news can be tacked onto as CC doesn't seem so keen on giving blow by blow Q2W updates.

It's no good telling us today. Why didn't you tell us this yesterday?

It's not a surprise. It's always like this on AIM. SP goes up on good but non-revenue related news, then drifts back down on no further news.

Revenue that means a further fund raise won't be needed for the foreseeable should push the SP up.

In my memory, AffyXell is down to IPO on KOSDAQ, a Korean market, but if anyone can link to where it says it will IPO on NASDAQ, that would be good.

https://www.investopedia.com/terms/k/koreastockexchange.asp